Existing users Log In New users Sign up

Erythrocyte membrane in type 2 diabetes mellitus

DISCOVERIES (ISSN 2359-7232), 2016, April-June issue


Gabreanu GR, Angelescu S. Erythrocyte membrane in type 2 diabetes mellitus. Discoveries 2016, April-June; 4(2): e60. DOI: 10.15190/d.2016.7

Submitted: June 17, 2016; Revised: June 30, 2016; Accepted: June 30, 2016; Published: June 30, 2016;

 GO BACK to 2016, April-June issue


Erythrocyte membrane in type 2 diabetes mellitus

Georgiana Roxana Gabreanu, Silvana Angelescu*

Hematology Department, Coltea Clinical Hospital, Bucharest, Romania

*Correspondence to: Silvana Angelescu, MD, Hematology Department, Coltea Clinical Hospital, Bucharest, Romania; Email: sangelescu21@gmail.com 


Type 2 diabetes mellitus represents a major public health challenge, due to the continuously growing prevalence and the complexity of the diabetic complications. Hyperglycemia seems to be the main mechanism for the disease progression. During erythrocyte’s long life span, erythrocyte membranes are affected by the chronic exposure to glucose, which triggers several biochemical modifications that lead to both structural and functional disruption, which are further involved in the physiopathology of diabetes and its complications. Non-enzymatic protein glycation of red blood cell membrane proteins occur in two phases: early glycation, characterized by Schiff bases and Amadouri compounds formation, and advanced glycation, characterized by advanced glycation end products (AGEs). These products could be valuable tools for early diagnosis or biomarkers for disease progression, depending on how advanced they are in the glycation process. Advanced glycated end products were linked with diabetic complications. Also, lipid peroxidation and decreased activity of the enzyme pumps occur in the erythrocyte membrane of the diabetic patients. The investigation of lipid rafts and erythrocyte membrane fatty acids are a valuable tool for long-term monitoring of metabolic status. Further investigation of the erythrocyte membrane could provide novel biomarkers for monitoring of diabetes and its complications. 

Access full text of the manuscript here: 


1. International Diabetes Federation. IDF Diabetes Atlas, 1st ed. Brussels, Belgium: International Diabetes Federation, 2000.

2. International Diabetes Federation. IDF Diabetes Atlas, 7th ed. Brussels, Belgium: International Diabetes Federation, 2015.

3. Viskupicova J, Blaskovic D, Galiniak S, Soszyński M, Bartosz G, Horakova L, Sadowska-Bartosz I. Effect of high glucose concentrations on human erythrocytes in vitro. Redox Biol. 2015. 5:381-7.

4. Maillard LC. Action des acides aminés sur les sucres: formation des mélanoidines par voie méthodique. C.R. Acad. Sci. 1912. 154: 66–68.

5. Finot PA. Historical perspective of the Maillard reaction in food science. Ann N Y Acad Sci. 2005. 1043:1-8.

6. Holmquist WR, Schroeder WA. A new N-terminal blocking group involving a Schiff base in hemoglobin AIc. Biochemistry. 1966. 5(8):2489-503.

7. Bookchin RM, Gallop PM. Structure of hemoglobin AIc: nature of the N-terminal beta chain blocking group. Biochem Biophys Res Commun. 1968. 32(1):86-93.

8. Rahbar S. The discovery of glycated hemoglobin: a major event in the study of nonenzymatic chemistry in biological systems. Ann N Y Acad Sci. 2005. 1043:9-19.

9. Gillery P. A history of HbA1c through Clinical Chemistry and Laboratory Medicine. Clin Chem Lab Med. 2013. 51(1):65-74. 

10. Dagogo-Jack S. Piftalls in the use of HbA1(c) as a diagnostic test: the ethnic conundrum, Nat Rev Endocrinol. 2010. 6(10):589-93.

11. Shepard JG, Airee A, Dake AW, McFarland MS, Vora A. Limitations of A1c Interpretation. South Med J. 2015. 108(12):724-9. 

12. Takahashi S Uchino H, Shimizu T, Kanazawa A, Tamura Y, Sakai K, Watada H, Hirose T, Kawamori R, Tanaka Y. Comparison of glycated albumin (GA) and glycated hemoglobin (HbA1c) in type 2 diabetic patients: usefulness of GA for evaluation of short-term changes in glycemic control. Endocr J. 2007. 54(1):139-44. 

13. Raghav A, Ahmad J. Glycated serum albumin: a potential disease marker and an intermediate index of diabetes control. Diabetes Metab Syndr. 2014. 8(4):245-51. 

14. Zhang Q, Tang N, Schepmoes AA, Phillips LS, Smith RD, Metz TO. Proteomic profiling of nonenzymatically glycated proteins in human plasma and erythrocyte membranes. J Proteome Res. 2008. 7(5):2025-32

15. Cho SJ, Roman G, Yeboah F, Konishi Y. The road to advanced glycation end products: a mechanistic perspective. Curr Med Chem. 2007. 14(15):1653-71.

16. Goh SY, Cooper ME. Clinical review: The role of advanced glycation end products in progression and complications of diabetes. J Clin Endocrinol Metab. 2008. 93(4):1143-52. 

17. De Oliveira S, Saldanha C. An overview about erythrocyte membrane. Clin Hemorheol Microcirc. 2010. 44(1):63-74. 

18. Zhang Q, Monroe ME, Schepmoes AA, Clauss TR, Gritsenko MA, Meng D, Petyuk VA, Smith RD, Metz TO. Comprehensive identification of glycated peptides and their glycation motifs in plasma and erythrocytes of control and diabetic subjects. J Proteome Res. 2011. 10(7):3076-88. 

19. Niwa T, Katsuzaki T, Miyazaki S, Miyazaki T, Ishizaki Y, Hayase F, Tatemichi N, Takei Y. Immunohistochemical detection of imidazolone, a novel advanced glycation end product, in kidneys and aortas of diabetic patients. J Clin Invest. 1997. 99(6):1272-80.

20. Yamaguchi M, Nakamura N, Nakano K, Kitagawa Y, Shigeta H, Hasegawa G, Ienaga K, Nakamura K, Nakazawa Y, Fukui I, Obayashi H, Kondo M. Immunochemical quantification of crossline as a fluorescent advanced glycation endproduct in erythrocyte membrane proteins from diabetic patients with or without retinopathy. Diabet Med. 1998. 15(6):458-62.

21. Portero-Otín M, Pamplona R, Bellmunt MJ, Bergua M, Prat J. Glycaemic control and in vivo non-oxidative Maillard reaction: urinary excretion of pyrraline in diabetes patients. Eur J Clin Invest. 1997. 27(9):767-73.

22. Nε-(carboxymethyl)-lysine, White Matter, and Cognitive Function in Diabetes Patients. Zhang JH, Xu HZ, Shen QF, Lin YZ, Sun CK, Sha L, Ge YS, Liu Y, Wang C. Can J Neurol Sci. 2016. 4:1-5. 

23. Morales S, García-Salcedo JA, Muñoz-Torres M. Pentosidine: a new biomarker in diabetes mellitus complications. Med Clin (Barc). 2011. 136(7):298-302. 

24. Kerkeni M, Saïdi A, Bouzidi H, Letaief A, Ben Yahia S, Hammami M. Pentosidine as a biomarker for microvascular complications in type 2 diabetic patients. Diab Vasc Dis Res. 2013. 10(3):239-45. 

25. Kuwajima S. Immunochemical determination of advanced glycation end products in erythrocyte peripheral-membrane proteins from diabetic patients. Hokkaido Igaku Zasshi. 1993. 68(5):695-704.

26. Wautier JL, Wautier MP, Schmidt AM, Anderson GM, Hori O, Zoukourian C, Capron L, Chappey O, Yan SD, Brett J, et al. Advanced glycation end products (AGEs) on the surface of diabetic erythrocytes bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: a link between surface-associated AGEs and diabetic complications. Proc Natl Acad Sci U S A. 1994. 91(16):7742-6.

27. Aoki S, Hasegawa G, Shigeta H, Obayashi H, Fujii M, Kimura F, Moriwaki A, Nakamura N, Ienaga K, Nakamura K, Kondo M. Crossline levels in serum and erythrocyte membrane proteins from patients with diabetic nephropathy. Diabetes Res Clin Pract. 2000. 48(2):119-25.

28. Nicolay JP, Schneider J, Niemoeller OM, Artunc F, Portero-Otin M, Haik G Jr, Thornalley PJ, Schleicher E, Wieder T, Lang F. Stimulation of suicidal erythrocyte death by methylglyoxal. Cell Physiol Biochem. 2006. 18(4-5):223-32.

29. Lang KS, Duranton C, Poehlmann H, Myssina S, Bauer C, Lang F, Wieder T, Huber SM. Cation channels trigger apoptotic death of erythrocytes. Cell Death Differ. 2003. 10(2):249-56.

30. Calderón-Salinas JV, Muñoz-Reyes EG, Guerrero-Romero JF, Rodríguez-Morán M, Bracho-Riquelme RL, Carrera-Gracia MA, Quintanar-Escorza MA. Eryptosis and oxidative damage in type 2 diabetic mellitus patients with chronic kidney disease.  Mol Cell Biochem. 2011. 357(1-2):171-9. 

31. Inouye M, Hashimoto H, Mio T, Sumino K. Levels of lipid peroxidation product and glycated hemoglobin A1c in the erythrocytes of diabetic patients. Clin Chim Acta. 1998. 276(2):163-72.

32. Inouye M, Mio T, Sumino K. Glycated hemoglobin and lipid peroxidation in erythrocytes of diabetic patients. Metabolism. 1999. 48(2):205-9.

33. Inouye M, Mio T, Sumino K. Link between glycation and lipoxidation in red blood cells in diabetes. Clin Chim Acta. 1999. 285(1-2):35-44.

34. Jiang M, Jia L, Jiang W, Hu X, Zhou H, Gao X, Lu Z, Zhang Z. Protein disregulation in red blood cell membranes of type 2 diabetic patients. Biochem Biophys Res Commun. 2003. 309(1):196-200.

35. Jiang M, Ding Y, Su Y, Hu X, Li J, Zhang Z. Arginase-flotillin interaction brings arginase to red blood cell membrane. FEBS Lett. 2006. 580(28-29):6561-4. 

36. Wall R, Ross RP, Fitzgerald GF, Stanton C. Fatty acids from fish: the anti-inflammatory potential of long-chain omega-3 fatty acids. Nutr Rev. 2010. 68(5):280-9. 

37. S. Imamura, T. Morioka, Y. Yamazaki, R. Numaguchi, H. Urata, K. Motoyama, et al. Plasma polyunsaturated fatty acid profile and delta-5 desaturase activity are altered in patients with type 2 diabetes. Metabolism. 2014. 63 (11):1432–1438

38. Navarro-González JF, Mora-Fernández C. The role of inflammatory cytokines in diabetic nephropathy. J Am Soc Nephrol. 2008. 19(3):433-42.

39. Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol. 2011. 11(2):98-107. 

40. Gupta S, Gambhir JK, Kalra O, Gautam A, Shukla K, Mehndiratta M, Agarwal S, Shukla R. Association of biomarkers of inflammation and oxidative stress with the risk of chronic kidney disease in Type 2 diabetes mellitus in North Indian population. J Diabetes Complications. 2013. 27(6):548-52.

41. Domingueti CP, Dusse LM, Carvalho Md, de Sousa LP, Gomes KB, Fernandes AP. Diabetes mellitus: The linkage between oxidative stress, inflammation, hypercoagulability and vascular complications. J Diabetes Complications. 2016. 30(4):738-45

42. Sertoglu E, Uyanik M, Kayadibi H, Tapan. Erythrocyte membrane fatty acids may be superior to plasma fatty acids in patients with type 2 diabetes. Metabolism. 2015. 64(4):e1-2. 

43. Takkunen M, Agren J, Kuusisto J, Laakso M, Uusitupa M, Schwab U. Dietary fat in relation to erythrocyte fatty acid composition in men. Lipids. 2013. 48(11):1093-102. 

44. Sertoglu E, Kurt I, Tapan S, Uyanik M, Serdar MA, Kayadibi H, El-Fawaeir S. Comparison of plasma and erythrocyte membrane fatty acid compositions in patients with end-stage renal disease and type 2 diabetes mellitus. Chem Phys Lipids. 2014. 178:11-7. 

45. Mahendran Y, Ågren J, Uusitupa M, Cederberg H, Vangipurapu J, Stančáková A, Schwab U, Kuusisto J, Laakso M. Association of erythrocyte membrane fatty acids with changes in glycemia and risk of type 2 diabetes. Am J Clin Nutr. 2014. 99(1):79-85 

46. Mazzanti L, Rabini RA, Testa I, Bertoli E. Modifications induced by diabetes on the physicochemical and functional properties of erythrocyte plasma membrane. Eur J Clin Invest. 1989. 19(1):84-9.

47. Zadhoush F, Sadeghi M, Pourfarzam M. Biochemical changes in blood of type 2 diabetes with and without metabolic syndrome and their association with metabolic syndrome components. J Res Med Sci. 2015. 20(8):763-70  

48. Kumar R. Biochemical changes in erythrocyte membrane in type 2 diabetes mellitus. Indian J Med Sci. 2012. 66(5-6):131-5. 

49. Shahid SM, Rafique R, Mahboob T. Electrolytes and sodium transport mechanism in diabetes mellitus. Pak J Pharm Sci. 2005. 18(2):6-10.

50. Fujita J, Tsuda K, Seno M, Obayashi H, Fukui I, Seino Y. Erythrocyte sodium-lithium countertransport activity as a marker of predisposition to hypertension and diabetic nephropathy in NIDDM. Diabetes Care. 1994. 17(9):977-82.

51. Fujita J, Tsuda K, Seno M, Obayashi H, Fukui I, Seino Y. Elevated erythrocyte sodium-lithium countertransport activity correlates with increased intracellular sodium and free calcium-ion concentration in type 2 diabetes. Diabet Med. 1996. 13(1):53-8.

52. Senior PA, Thomas TH, Marshall SM. Abnormal thiol group modulation of sodium-lithium countertransport and membrane fluidity is associated with a disturbed relationship between serum triacylglycerols and membrane function in type II diabetes. Clin Sci (Lond). 2000. 98(6):673-80.

53. Vareesangthip K, Panthongdee W, Shayakul C, Nitiyanant W, Ong-Aj-Yooth L. Abnormal kinetics of erythrocyte sodium lithium countertransport in patients with diabetic nephropathy in Thailand. J Med Assoc Thai. 2006. 89 Suppl 2:S48-53.

54. González Flecha FL, Castello PR, Caride AJ, Gagliardino JJ, Rossi JP. The erythrocyte calcium pump is inhibited by non-enzymic glycation: studies in situ and with the purified enzyme. Biochem J. 1993. 293(Pt 2):369-75.

55. González Flecha FL, Castello PR, Gagliardino JJ, Rossi JP. Molecular characterization of the glycated plasma membrane calcium pump. J Membr Biol. 1999. 171(1):25-34.

56. Raftos JE, Edgley A, Bookchin RM, Etzion Z, Lew VL, Tiffert T. Normal Ca2+ extrusion by the Ca2+ pump of intact red blood cells exposed to high glucose concentrations. Am J Physiol Cell Physiol. 2001. 280(6):C1449-54.

57. Lew VL, Daw N, Etzion Z, Tiffert T, Muoma A, Vanagas L, Bookchin RM. Effects of age-dependent membrane transport changes on the homeostasis of senescent human red blood cells. Blood. 2007. 110(4):1334-42. 

58. Bookchin RM, Etzion Z, Lew VL, Tiffert T. Preserved function of the plasma membrane calcium pump of red blood cells from diabetic subjects with high levels of glycated haemoglobin. Cell Calcium. 2009. 45(3):260-3. 

59. Balasubramanyam M, Balaji RA, Subashini B, Mohan V. Evidence for mechanistic alterations of Ca2+ homeostasis in Type 2 diabetes mellitus. Int J Exp Diabetes Res. 2001. 1(4):275-87.

News & Events Latest news from Discoveries

  • 2022, April| AWARDS!

    2022 Discoveries Award winning articles!

    - Kinal Bhatt et al. 2021 (Larking Health System, FL, USA); Bhatt K, Agolli A, Patel MH, et al. High mortality co-infections of COVID-19 patients: mucormycosis and other fungal infections. Discoveries. 2021;9(1):e126. 
    27 citations in the past 1 year - $1000 prize

    - Hasnain Jan et al. 2020 (Quaid-i-Azam University, Pakistan); Jan H, Faisal S, Khan A, et al. COVID-19: Review of Epidemiology and Potential Treatments Against 2019 Novel Coronavirus. Discoveries. 2020;8(2):e108. 
    23 citations in the past 2 years - $400 prize

    Congratulations! Prizes will be received by the awardees in July 2022!

  • 2021, July| 2021, Jul-September

    Due to the high volume of the submitted articles, both Discoveries and Discoveries Reports are experiencing processing and publication delays during the months of July-September 2021. We will get back to the normal processing and publication times starting in October 2021. Note that our editorial and administrativ work is fully funded by our publishing house at this time and we are striving to KEEP THE NO FEE/NO CHARGE strategy in place as long as possible. 

  • 2021, January| AWARDS!

    2022 DISCOVERIES AWARDS! Discoveries will offer $1000 and $400 awards in early 2022, for the most cited (2021 ISI Citations) and visible articles published in 2018-2021.

  • 2020, November| Follow us on Twitter!

    You can now follow the latest Discoveries news and updates on Twitter! (@DiscoveriesNews) 

  • 2020, August| For Authors!

    Due to a high volume of article submissions, our peer-review process takes more than usual. The pre-screening decision is released in 1-2 days, while the peer-review process lasts between 10 and 20 days.  

  • 2020, April | For Authors!

    WE DO NOT TOLERATE ANY MISCONDUCT! Please be aware that we are testing all received articles with specialized software for PLAGIARISM and WE WILL TAKE MEASURES if your article is already published or in consideration for publication by other journals! This may result in serious professional consequences for the authors. The latest striking case is the following article which is already published and was re-submitted here.  

  • 2020, April | For Authors!

    We are happy to let you know that all articles published in Discoveries are now included in PubMedCentral (PMC). New accepted articles will be included in PMC and PubMed within 1-2 weeks after their publication.

  • 2020, January | For Authors!

    Starting in January 2020, Discoveries will also consider articles submitted by Discoveries' Editorial Board members. However, only a small number of such articles (maximum 4 articles/year) will be considered for publication after the peer-review process, and the authors who are also our editors will be clearly disclosed on our website.  

  • 2019, September | Indexed by PMC

    Discoveries is now indexed by PubMedCentral and Pubmed. The agreement with US National Library of Medicine was signed on September 10, 2019. Our next step is ISI Web of Science indexing. NOTE: previously published articles will be included on PubMed in early 2020.

  • 2019, September | PubMed inclusion!

    We are happy to let you know that Discoveries successfuly passed the last step (Technical Review) required for PubMedCentral and PubMed inclusion!

  • 2019, July | PubMed inclusion News!

    We are happy to receive positive comments from PMC/NLM-NIH regarding Discoveries' last step (Technical Review) required for PubMedCentral and PubMed inclusion. We will let you know once whole indexing process is completed. 

  • 2019| Sharing and Distribution!

    All articles published in Discoveries are Open Access articles distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited and it is not used for commercial purposes.

  • 2018-2019 | For Authors!

    From now on and for at least 1 year, we will only accept articles from authors that are NOT members of Discoveries' Editorial Board. All articles submitted by our editors will be immediately rejected until further notice (one accepted article was already rejected). 

  • 2018 | PubMed inclusion News!

    Discoveries successfully passed the Scientific Quality Review by NLM-NIH for PubMedCentral and PubMed indexing. This is the first and the most important step towards PubMedCentral and PubMed indexing! The second (last) step is the Technical Review.

  • 2016, April | Faster Peer-Review

    Starting on April 13th 2016, all articles selected for a peer-review will receive the post peer-review decision within ~10 days. The initial pre-screening time will remain the same (48h from the submission of the manuscript). This decision will significantly accelerate the publication, with no effect on the quality of the peer-review process.

  • 2016, February | Manuscript submission

    Discoveries is commited to excellence, quality and high editorial standards. We are receiving an increasing number of manuscripts for which the identity of the authors/corresponding author can't be verified. Please NOTE that ALL these articles were and will be immediately REJECTED. Indicating an institutional email address is the easiest way to overcome this problem! Moreover, we do not accept any pressure on our editorial board to accept a manuscript. This results in a prompt rejection of the article.

    Editorial Policies
  • 2016, January | Main Objective

    After reaching all proposed milestones until now (including being indexed by Google Scholar in 2014), Discoveries' next Aim is PubMed indexing of all its articles (already published and upcoming). There will be no charge for the submission or publication of articles before Discoveries is indexed.

  • 2015, August | Discoveries - on PubMed

    We are happy to announce that our first Discoveries articles were included in PMC and PubMed. More articles (submitted by NIH funded authors) are now processed for being included.

    Discoveries articles now on PubMed
  • 2015, April | Special Issue

    DISCOVERIES published the SPECIAL ISSUE entitled "INFLAMMATION BETWEEN DEFENSE AND DISEASE: Impact on Tissue Repair and Chronic Sickness".

    Special Issue on "Inflammation"
  • 2015 | Ischemia Collection

    DISCOVERIES launched a call for papers for a Collection of Articles with focus on "ISCHEMIA". If you are interested to submit a manuscript, please contact us at info@discoveriesjournals.org

  • 2014, September | Special Issue

    DISCOVERIES just publish the SPECIAL ISSUE entitled "CELL SECRETION & MEMBRANE FUSION" in September 2014. Initially scheduled for publication between October 2014-March 2015, this issue was successfully published earlier than scheduled. 

    Special Issue
  • 2014, April | Indexed by Google Scholar

    All our published articles are now indexed by Google Scholar! First citations to Discoveries articles are included! Search for the article's title (recommended) or the authors:

    Google Scholar Search
  • 2014 | DISCOVERIES

    DOIs (Digital Object Identifiers) are now assigned to all our published manuscripts in Discoveries. DOI uniquely identifies an article and is provided by CrossRef.

  • 2013, July | Manuscript Submission

    Submit your manuscript FREE, FAST and EASY ! (in less than 1 minute)! There are NO fees for the manuscript submission or publishing of the accepted manuscripts.
    read more

  • 2013, July | DISCOVERIES

    We are now ACCEPTING MANUSCRIPTS for publishing in DISCOVERIES. We aim publishing a small number of high impact experimental articles & reviews (around 40/year) to maintain a high impact factor. Domains of interest: all areas related to Medicine, Biology and Chemistry ...

    read more
Member Login
Free Registration Click here to sign up
Copyright © 2013 Applied Systems. All Rights Reserved.